SocialPicks Monitor new  |    Stock Idea Community
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Dynavax Technologies Corp.  (DVAX) Trade Now »     Rate DVAX  -  Discuss DVAX  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
77.0%
Top:
0.0%
Rate DVAX:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

DVAX: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community



From the Blogosphere

Unusual 11 Mid-Day Movers 10/22: UAUA, CHRW, EEV, CRI Higher; DVAX, CVH, KND, SNDK Lower
Dynavax (NASDAQ: DVAX) 78.1% LOWER; The FDA has advised Dynavax and Merck that the balance of risk versus potential benefit no longer favors continued clinical evaluation of HEPLISAV in healthy adults and children. The FDA has also advised the companies that there may be potential for an acceptable risk versus benefit profile for HEPLISAV in patients with renal failure, and requested additional information from the companies before considering further pursuit of clinical studies in those patients. Dynavax and Merck are evaluating the FDA's response in considering next steps. In the meantime...
By  Street Insider   (-57.05%  risk: aggressive)  10/22/08 Comment


Morning Movers 10/22: Coventry Health (CVH) Sinks On Results, SanDisk (SNDK) Down After Offer Pulled; Apple (AAPL) Higher On EPS

StreetInsider.com Morning Movers:

ICO Global Communications Limited (NASDAQ: ICOG) 100% HIGHER; was awarded at least $371 million in its litigation with The Boeing Company (NYSE: BA) and Boeing Satellite Systems International.

Dynavax (NASDAQ: DVAX) 40% LOWER; The FDA has advised Dynavax and Merck that the balance of risk versus potential benefit no longer favors continued clinical evaluation of HEPLISAV in healthy adults and children. The FDA has also advised the companies that there may be potential for an acceptable risk versus benefit profile for HEPLISAV in patients with renal failure,

...
By  Street Insider   (-57.05%  risk: aggressive)  10/22/08 Comment


Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) Climb on Successful Phase 3 Trial and Second Quarter Financial Results
Logo1
34%

Dynavax Technologies Corporation (NASDAQ: DVAX), a developer of innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergy, cancer and chronic inflammatory diseases by utilizing versatile, proprietary approaches to alter immune system responses, recently announced the results form a Phase 3 clinical trial and the company’s second quarter financial results.

Shares of Dynavax Technologies climbed higher earlier this week after the company announced positive top line results from a Phase 3 clinical trial comparing HEPLISAVâ„¢, an investigational hepatitis B viru

...
By  StraightStocks   (-20.84%  risk: conservative)  08/08/08 Comment


Clinical Hold on Dynavax Drug DVAX
-83.90%
in 145 days
We are intrigued by DynavaxÂ?s proprietary ImmunoStimulatory Sequence technology, but disappointed with the clinical hold on its lead candidate Heplisav. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was ad...
By  Zacks.com   (-24.32%  risk: conservative)  07/10/08 Comment


Pre-Open Movers 5/16: Pharmacopeia (PCOP) Up on Positive Drug Data, Dynavax (DVAX) Lower on Drug Data
StreetInsider.com Pre-Open Movers:

Pharmacopeia (Nasdaq: PCOP) 42% HIGHER; announced that PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), showed statistically significant blood pressure reductions in a Phase 2a study in patients with mild to moderate hypertension.

Dynavax Technologies Corporation (Nasdaq: DVAX) 18% LOWER; reported primary endpoint data from a chamber study of TOLAMBA that showed a measurable clinical benefit, reducing total nasal symptom score by 41% vs. placebo in 253 patients in the intent-to-treat population (p=0.09) and by 51% vs. placebo in 222 pat...
By  Street Insider   (-57.05%  risk: aggressive)  05/16/08 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 18.70 +40.85% 175
2 Gerald Greene 17.51 +40.49% 57
3 krprasad 16.70 +18.24% 7
4 The Big Bear 14.22 +37.54% 211
5 akiralegrand 13.70 +16.71% 40


POPULAR STOCKS
Symbol Company Name Sentiment
WMT WalMart Stores Inc
LEH Lehman Brothers Holdings Inc
MA MasterCard Inc
F Ford Motor Company
CSCO Cisco Systems Inc
JNJ Johnson & Johnson

TODAY'S HEADLINES

TODAY'S TOP PICKS

 


StreetInsider.com on DVAX

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Dynavax Technologies Corp. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch